Trial Profile
RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Cisplatin
- Indications Small cell lung cancer
- Focus Adverse reactions
- 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
- 30 Jun 2009 Additional lead trial investigator Hageboutros A identified as reported by New Jersey Cancer Trial Connect.
- 04 Nov 2008 Checked against ClinicalTrials.gov record.